A growing number of studies have reported that routinely monitored per- and polyfluoroalkyl substances (PFAS) are not sufficient to explain the extractable organic fluorine (EOF) measured in human blood. In this study, we address this gap by screening pooled human serum collected over 3 decades (1986-2015) in Tromsø (Norway) for >5000 PFAS and >300 fluorinated pharmaceuticals. We combined multiple analytical techniques (direct infusion Fourier transform ion cyclotron resonance mass spectrometry, liquid chromatography-Orbitrap-high-resolution mass spectrometry, and total oxidizable precursors assay) in a three-step suspect screening process which aimed at unequivocal suspect identification. This approach uncovered the presence of one PFAS and eight fluorinated pharmaceuticals (including some metabolites) in human serum. While the PFAS suspect only accounted for 2-4% of the EOF, fluorinated pharmaceuticals accounted for 0-63% of the EOF, and their contribution increased in recent years. Although fluorinated pharmaceuticals often contain only 1-3 fluorine atoms, our results indicate that they can contribute significantly to the EOF. Indeed, the contribution from fluorinated pharmaceuticals allowed us to close the organofluorine mass balance in pooled serum from 2015, indicating a good understanding of organofluorine compounds in humans. However, a portion of the EOF in human serum from 1986 and 2007 still remained unexplained.

The unique properties of per- and polyfluoroalkyl substances (PFAS) have led to their extensive use in consumer products, including ski wax. Based on the risks associated with PFAS, and to align with PFAS regulations, the international ski federation (FIS) implemented a ban on products containing \"C8 fluorocarbons/perfluorooctanoate (PFOA)\" at all FIS events from the 2021/2022 season, leading manufactures to shift their formulations towards short-chain PFAS chemistries. To date, most studies characterising PFAS in ski waxes have measured a suite of individual substances using targeted analytical approaches. However, the fraction of total fluorine (TF) in the wax accounted for by these substances remains unclear. In this study, we sought to address this question by applying a multi-platform, fluorine mass balance approach to a total of 10 commercially available ski wax products. Analysis of TF by combustion ion chromatography (CIC) revealed concentrations of 1040-51700 μg F g-1 for the different fluorinated waxes. In comparison, extractable organic fluorine (EOF) determined in methanol extracts by CIC (and later confirmed by inductively-coupled plasma-mass spectrometry and 19F- nuclear magnetic resonance spectroscopy) ranged from 92 to 3160 μg g-1, accounting for only 3-8.8 % of total fluorine (TF). Further characterisation of extracts by cyclic ion mobility-mass spectrometry (IMS) revealed 15 individual PFAS with perfluoroalkyl carboxylic acid concentrations up to 33 μg F g-1, and 3 products exceeding the regulatory limit for PFOA (0.025 μg g-1) by a factor of up to 100. The sum of all PFAS accounted for only 0.01-1.0 % of EOF, implying a high percentage of unidentified PFAS, thus, pyrolysis gas chromatography-mass spectrometry was used to provide evidence of the nature of the non-extractable fluorine present in the ski wax products.

High-frequency ultrasound (sonolysis) has been shown as a practical approach for mineralizing PFAS in highly concentrated PFAS waste. However, a fluorine mass balance approach showing complete mineralization for ultrasound treatment has not been elucidated. The impact of ultrasonic power density (W/L) and the presence of co-occurring PFAS on the degradation of individual PFAS are not well understood. In this research, the performance of a 10L sonochemical reactor was assessed for treating synthetic high-concentration PFAS waste with carboxylic and sulfonic perfluoroalkyl surfactants ranging in chain length from four to eight carbons at three different initial concentrations: 6, 55, 183 μM. The mass balance for fluorine was performed using three analytical techniques: triple quadrupole liquid chromatography-mass spectrometry, a fluoride ion selective electrode, and 19F nuclear magnetic resonance. The test results showed near complete mineralization of PFAS in the waste without the formation of intermediate fluorinated by-products. The PFAS mineralization efficiency of the sonolysis treatment at two different power densities for similar initial concentrations were almost identical; the G value at 145 W/L was 9.7*10-3 g/kWh, whereas the G value at 90 W/L was 9.3*10-3 g/kWh. The results of this study highlight the implications for the scalability of the sonolytic process to treat high-concentration PFAS waste.